Mutations

SORL1 R1729H

Overview

Clinical Phenotype: Alzheimer's Disease
Position: (GRCh38/hg38):Chr11:121608123 G>A
Position: (GRCh37/hg19):Chr11:121478832 G>A
dbSNP ID: rs534646732
Coding/Non-Coding: Coding
DNA Change: Substitution
Expected Protein Consequence: Missense
Codon Change: CGT to CAT
Reference Isoform: SORL1 Isoform 1 (2214 aa)
Genomic Region: Exon 38

Findings

In a study that included 15,808 Alzheimer’s cases and 16,097 control subjects from multiple European and American cohorts, this allele was observed seven times—three times among the AD cases and four times among the controls (Holstege et al., 2022). A mega-analysis of these data did not find an association between the variant and AD risk.

Previously, one control and one early onset Alzheimer’s patient were identified as heterozygous carriers of this variant in a French cohort of 927 late onset AD cases, 852 early onset AD cases and 1,273 controls from the Alzheimer Disease Exome Sequencing France (ADESFR) project (Bellenguez et al., 2017). The affected carrier was 65 years old at symptom onset, with an APOE genotype of e2/e3 (Nicolas et al., 2018).

Another Alzheimer’s patient, 56 years of age, was also a heterozygous carrier in a Dutch sample of 640 AD cases and 1268 controls (Holstege et al., 2017).

The R1729H variant was found in one of 5198 AD cases and two of 4491 controls in a dataset from the Alzheimer’s Disease Sequencing Project (ADSP), consisting of subjects of non-Hispanic Caucasian ancestry from whom whole-exome sequencing data were available (Campion et al., 2019).

ADESFR, ADSP, and the cohorts comprising the Dutch sample all contributed data to the 2022 study cited above.

The R1729H variant is classified as “uncertain: most likely not pathogenic” by the criteria of Holstege et al. (Holstege et al., 2017).

Functional Consequences

The variant was predicted to be deleterious by SIFT, disease-causing by Mutation Taster, and probably damaging by PolyPhen-2 (Bellenguez et al., 2017).

In a study investigating the effects of SORL1 missense mutations on protein processing, the R1729H variant did not affect the maturation (glycosylation) of SORL1 overexpressed in HEK293 cells (Rovelet-Lecrux et al., 2021).

Table

Risk Allele(s) N
Cases | Controls
aAllele frequency
Cases | Controls
Reported association measurements Ancestry
(Cohort)
Reference
Large-scale studies, meta- and mega-analyses
A 15,808 | 16,097 9.49×10-5 | 1.24×10-4 OR = 0.50
[CI: 0.10-2.42]
p = 0.38
Multiple European and American cohorts Holstege et al., 2022
(mega-analysis)
Other studies
A 852 (EOAD) | 927 (LOAD) | 1273 (CTRL) 5.87×10-4  | 0 | 3.93×10-4   French
(Alzheimer Disease Exome Sequencing France (ADESFR))
Bellenguez et al., 2017
A 5198 | 4491 9.62×10-5 | 1.11×10-4   Non-Hispanic Caucasian
(Alzheimer’s Disease Sequencing Project (ADSP))
Campion et al., 2019
A 640 | 1268 7.81×10-4 | 0   Dutch
(Rotterdam Study, Amsterdam Dementia Cohort, Alzheimer Centrum Zuidwest Nederland (ACZN), 100-plus Study)
Holstege et al., 2017
A 332 | 676 0 | 0   UK and North American Caucasian
(NIH-UCL, Knight ADRC, ADNI, Cache County Study on Memory in Aging)
Sassi et al., 2016,
Campion et al., 2019
A 1255 | 1938 0 | 0   European
(European Early-Onset Dementia Consortium)
Verheijen et al., 2016,
Campion et al., 2019

aAllele frequencies as reported by study authors or calculated by Alzforum curators from data provided in the study, assuming heterozygosity if not explicitly stated in the paper.

This table is meant to convey the range of results reported in the literature. As specific analyses, including co-variates, differ among studies, this information is not intended to be used for quantitative comparisons, and readers are encouraged to refer to the original papers. Thresholds for statistical significance were defined by the authors of each study. (Significant results are in bold.) Note that data from some cohorts may have contributed to multiple studies, so each row does not necessarily represent an independent dataset. While every effort was made to be accurate, readers should confirm any values that are critical for their applications.

Last Updated: 18 Jul 2024

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

Paper Citations

  1. . Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease. Nat Genet. 2022 Dec;54(12):1786-1794. Epub 2022 Nov 21 PubMed.
  2. . Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiol Aging. 2017 Nov;59:220.e1-220.e9. Epub 2017 Jul 14 PubMed.
  3. . Somatic variants in autosomal dominant genes are a rare cause of sporadic Alzheimer's disease. Alzheimers Dement. 2018 Dec;14(12):1632-1639. Epub 2018 Aug 13 PubMed.
  4. . Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. Eur J Hum Genet. 2017 Aug;25(8):973-981. Epub 2017 May 24 PubMed.
  5. . SORL1 genetic variants and Alzheimer disease risk: a literature review and meta-analysis of sequencing data. Acta Neuropathol. 2019 Aug;138(2):173-186. Epub 2019 Mar 25 PubMed.
  6. . Influence of Coding Variability in APP-Aβ Metabolism Genes in Sporadic Alzheimer's Disease. PLoS One. 2016;11(6):e0150079. Epub 2016 Jun 1 PubMed.
  7. . A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. Acta Neuropathol. 2016 Aug;132(2):213-24. Epub 2016 Mar 30 PubMed.
  8. . Impaired SorLA maturation and trafficking as a new mechanism for SORL1 missense variants in Alzheimer disease. Acta Neuropathol Commun. 2021 Dec 18;9(1):196. PubMed.

Further Reading

No Available Further Reading

Protein Diagram

Primary Papers

  1. . Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. Eur J Hum Genet. 2017 Aug;25(8):973-981. Epub 2017 May 24 PubMed.

Other mutations at this position

Disclaimer: Alzforum does not provide medical advice. The Content is for informational, educational, research and reference purposes only and is not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on Alzforum.